MO‐G‐304‐01: FEATURED PRESENTATION: Expanding the Knowledge Base for Data‐Driven Treatment Planning: Incorporating Patient Outcome Models

• Published in: Medical physics (Lancaster) 2015-06, Vol.42 (6Part30), p.3579-3580
• Main Authors: Robertson, SP, Quon, H, Cheng, Z, Moore, JA, Bowers, M, McNutt, TR
• Format: Article
• Language: English
• Subjects: 60 APPLIED LIFE SCIENCES; ANIMAL TISSUES; Biomedical modeling; Cancer; Computer modeling; Dosimetry; GLANDS; HAZARDS; HEAD; Knowledge bases; Medical treatment planning; NECK; NEOPLASMS; PATIENTS; PLANNING; RADIATION DOSES; RADIATION PROTECTION AND DOSIMETRY; RADIOTHERAPY; Tissues
• ISSN: 0094-2405; 2473-4209
• DOI: 10.1118/1.4925472

Purpose: To extend the capabilities of knowledge‐based treatment planning beyond simple dose queries by incorporating validated patient outcome models. Methods: From an analytic, relational database of 684 head and neck cancer patients, 372 patients were identified having dose data for both left and right parotid glands as well as baseline and follow‐up xerostomia assessments. For each existing patient, knowledge‐based treatment planning was simulated for by querying the dose‐volume histograms and geometric shape relationships (overlap volume histograms) for all other patients. Dose predictions were captured at normalized volume thresholds (NVT) of 0%, 10%, 20, 30%, 40%, 50%, and 85% and were compared with the actual achieved doses using the Wilcoxon signed‐rank test. Next, a logistic regression model was used to predict the maximum severity of xerostomia up to three months following radiotherapy. Baseline xerostomia scores were subtracted from follow‐up assessments and were also included in the model. The relative risks from predicted doses and actual doses were computed and compared. Results: The predicted doses for both parotid glands were significantly less than the achieved doses (p < 0.0001), with differences ranging from 830 cGy ± 1270 cGy (0% NVT) to 1673 cGy ± 1197 cGy (30% NVT). The modelled risk of xerostomia ranged from 54% to 64% for achieved doses and from 33% to 51% for the dose predictions. Relative risks varied from 1.24 to 1.87, with maximum relative risk occurring at 85% NVT. Conclusions: Data‐driven generation of treatment planning objectives without consideration of the underlying normal tissue complication probability may Result in inferior plans, even if quality metrics indicate otherwise. Inclusion of complication models in knowledge‐based treatment planning is necessary in order to close the feedback loop between radiotherapy treatments and patient outcomes. Future work includes advancing and validating complication models in the context of knowledge‐based treatment planning. This work is supported by Philips Radiation Oncology Systems.